Label: LIDODOSE- lidocaine hydrochloride gel

  • Category: HUMAN OTC DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: OTC monograph not final

DISCLAIMER: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

Drug Label Information

Updated October 4, 2022

If you are a consumer or patient please visit this version.

  • Dosage and Administration

    Adults and children 2 years of age and older: Apply using a gloved hand. Swirl the applicator tip prior to removing swab from the pouch and apply to area 3-5 minutes prior to procedure not more than 4 times daily.

    Children under 2 years of age: consult a physician.

  • Usage

    Pain relief

  • Warning: for external use only.

    Methemoglobinemia


    Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.


    Signs and symptoms of methemoglobinemia may occur immediately or may be delayed some hours after exposure and are characterized by a cyanotic skin discoloration and abnormal coloration of the blood. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death. Discontinue LidoDose and any other oxidizing agents. Depending on the severity of the symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydration. More severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen.

    Avoid contact with eyes.

    Stop use and consult a physician if condition worsens, or if symptoms persist for more than 7 days or clear up and occur again within a few days. Do not use in large quantities, particularly over raw surfaces or blistered areas.

  • DRUG INTERACTIONS

    Patients that are administered local anesthetics may be at increased risk of developing methemoglobinemia when concurrently exposed to the following oxidizing agents:

    Class Examples
    Nitrates/Nitrites nitroglycerin, nitroprusside, nitric oxide, nitrous oxide
    Local anesthetics benzocaine, lidocaine, bupivacaine, inepivacaine, tetracaine, prilocaine, procaine, articaine, ropivacaine
    Antineoplastic agents cyclophosphamide, flutamide, rasburicase, ifosfamide, hydroxyurea
    Antibiotics dapsone, sulfonamides, nitrofurantoin, para¬aminosalicylic acid
    Antimalarials chloroquine, primaquine
    Anticonvulsants phenytoin, sodium valproate, phenobarbital
    Other drugs acetaminophen, metoclopramide, sulfa drugs (i.e., sulfasalazine), quinine

  • Keep out of reach of children

    If swallowed, get medical help or contact a Poison Control Center right away.

  • Storage

    Store between 68 and 77 F (20 - 25 C), with allowed excursions between 59 and 86 F (15 - 30 C). Protect from freezing. (See USP Controlled Room Temperature).

  • PATIENT COUNSELING INFORMATION

    Inform patients that use of local anesthetics may cause methemoglobinemia, a serious condition that must be treated promptly. Advise patients or caregivers to stop use and seek immediate medical attention if they or someone in their care experience the following signs or symptoms: pale, gray, or blue colored skin (cyanosis); headache; rapid heart rate; shortness of breath; lightheadedness; or fatigue.

  • Active Ingredients:

    Lidocaine Hydrochloride 3%

    Purpose:

    Anesthetic

  • Inactive Ingredients:

    Aqua (Deionized Water), Carbomer, Isopropyl Alcohol, Petrolatum, Polysorbate-20, Triethanolamine

  • SPL UNCLASSIFIED SECTION

    Please see product insert for additional information.

  • LIDO DOSE

    Carton
    Insert
    Label
  • INGREDIENTS AND APPEARANCE
    LIDODOSE 
    lidocaine hydrochloride gel
    Product Information
    Product TypeHUMAN OTC DRUGItem Code (Source)NDC:35781-0301
    Route of AdministrationTOPICAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    LIDOCAINE HYDROCHLORIDE (UNII: V13007Z41A) (LIDOCAINE - UNII:98PI200987) LIDOCAINE HYDROCHLORIDE ANHYDROUS3 mg  in 100 mL
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) (UNII: 4Q93RCW27E)  
    ISOPROPYL ALCOHOL (UNII: ND2M416302)  
    PETROLATUM (UNII: 4T6H12BN9U)  
    POLYSORBATE 20 (UNII: 7T1F30V5YH)  
    TRIETHANANOLAMINE PHENYLBENZIMIDAZOLE SULFONATE (UNII: TQA10H23WC)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:35781-0301-525 in 1 BOX01/01/2018
    1NDC:35781-0301-01 mL in 1 POUCH; Type 0: Not a Combination Product
    2NDC:35781-0301-1100 in 1 BOX01/01/2018
    2NDC:35781-0301-01 mL in 1 POUCH; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    OTC monograph not finalpart34801/01/2018
    Labeler - Gensco Laboratories, LLC (831042325)